The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Novel Peptide Inhibitors of Angiotensin-converting Enzyme 2
Open accessAbstract
Angiotensin-converting enzyme 2 (ACE2), a recently identified human homolog of ACE, is a novel metallocarboxypeptidase with specificity, tissue distribution, and function distinct from those of ACE. ACE2 may play a unique role in the renin-angiotensin system and mediate cardiovascular and renal function. Here we report the discovery of ACE2 peptide inhibitors through selection of constrained peptide libraries displayed on phage. Six constrained peptide libraries were constructed and selected against FLAG-tagged ACE2 target. ACE2 peptide binders were identified and classified into five groups, based on their effects on ACE2 activity. Peptides from the first three classes exhibited none, weak, or moderate inhibition on ACE2. Peptides from the fourth class exhibited strong inhibition, with equilibrium inhibition constants (K(i) values) from 0.38 to 1.7 microm. Peptides from the fifth class exhibited very strong inhibition, with K(i) values < 0.14 microm. The most potent inhibitor, DX600, had a K(i) of 2.8 nm. Steady-state enzyme kinetic analysis showed that these potent ACE2 inhibitors exhibited a mixed competitive and non-competitive type of inhibition. They were not hydrolyzed by ACE2. Furthermore, they did not inhibit ACE activity, and thus were specific to ACE2. Finally, they also inhibited ACE2 activity toward its natural substrate angiotensin I, suggesting that they would be functional in vivo. As novel ACE2-specific peptide inhibitors, they should be useful in elucidation of ACE2 in vivo function, thus contributing to our better understanding of the biology of cardiovascular regulation. Our results also demonstrate that library selection by phage display technology can be a rapid and efficient way to discover potent and specific protease inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-converting enzyme 2 is an essential regulator of heart function
Crackower, M. A., Sarao, R., Oudit, G. Y., Yagil, C., Kozieradzki, I., Scanga, S. E., Oliveira-dos-Santos, A. J., da Costa, J., Zhang, L., Pei, Y., et al. (2002) · Nature · doi:10.1038/nature00786 · Cited by 1,733
Cited by
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Phage-encoded combinatorial chemical libraries based on bicyclic peptides
Heinis, C., Rutherford, T., Freund, S., & Winter, G. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.184 · Cited by 743
Candidate drugs against SARS-CoV-2 and COVID-19
McKee, D. L., Sternberg, A., Stange, U., Laufer, S., & Naujokat, C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104859 · Cited by 562
ACE2: from vasopeptidase to SARS virus receptor
Turner, A. J., Hiscox, J. A., & Hooper, N. M. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.04.001 · Cited by 517
Kuba, K., Imai, Y., Ohto-Nakanishi, T., & Penninger, J. M. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.06.003 · Cited by 480
Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets
Jiang, F., Yang, J., Zhang, Y., Dong, M., Wang, S., Zhang, Q., Liu, F. F., Zhang, K., & Zhang, C. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.59 · Cited by 426
ACE2, a new regulator of the renin–angiotensin system
Burrell, L. M., Johnston, C. I., Tikellis, C., & Cooper, M. E. (2004) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2004.03.001 · Cited by 362
ACE and ACE2 Activity in Diabetic Mice
Wysocki, J., Ye, M., Soler, M. J., Gurley, S. B., Xiao, H. D., Bernstein, K. E., Coffman, T. M., Chen, S., & Batlle, D. (2006) · Diabetes · doi:10.2337/db06-0033 · Cited by 339
Angiotensin‐converting enzyme 2 in the brain: properties and future directions
Xia, H., & Lazartigues, E. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05723.x · Cited by 321
Phage display-derived peptides as therapeutic alternatives to antibodies
Ladner, R. C., Sato, A. K., Gorzelany, J., & de Souza, M. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03104-6 · Cited by 301
Self-citationHuman Recombinant ACE2 Reduces the Progression of Diabetic Nephropathy
Oudit, G. Y., Liu, G. C., Zhong, J., Basu, R., Chow, F. L., Zhou, J., Loibner, H., Janzek, E., Schuster, M., Penninger, J. M., et al. (2010) · Diabetes · doi:10.2337/db09-1218 · Cited by 300
ACE2/ANG-(1–7)/Mas pathway in the brain: the axis of good
Xu, P., Sriramula, S., & Lazartigues, E. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00222.2010 · Cited by 283
ACE2 of the heart: From angiotensin I to angiotensin (1–7)
KEIDAR, S., KAPLAN, M., & GAMLIELLAZAROVICH, A. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.09.006 · Cited by 278
Ocaranza, M. P., Godoy, I., Jalil, J. E., Varas, M., Collantes, P., Pinto, M., Roman, M., Ramirez, C., Copaja, M., Diaz-Araya, G., et al. (2006) · Hypertension · doi:10.1161/01.hyp.0000237862.94083.45 · Cited by 273
Angiotensin-Converting Enzyme II in the Heart and the Kidney
Danilczyk, U., & Penninger, J. M. (2006) · Circulation Research · doi:10.1161/01.res.0000205761.22353.5f · Cited by 269
Chen, H., Peng, J., Wang, T., Wen, J., Chen, S., Huang, Y., & Zhang, Y. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115370 · Cited by 19
Dermawan, D., & Alotaiq, N. (2025) · Scientific Reports · doi:10.1038/s41598-025-93683-1 · Cited by 19
Development and structure-guided characterization of a novel ACE2-binding macrocyclic peptide
Benoit, R. M., Wang, J., Beyer, D., Abbas, A., Rodrigues, M. J., Wieser, M. M., Deupi, X., Müller, C., Suga, H., & Bode, J. W. (2026) · Journal of Structural Biology: X · doi:10.1016/j.yjsbx.2026.100145
“WJL-63 binds further towards the side of the catalytic cleft compared to the predicted binding of the peptide DX600 (Beyer et al., 2023), a peptide that was cyclized through a disulfide bond (Huang et al., 2003) and was predicted to directly interact with the catalytic zinc ion (Fig.”
Metadata
- Authors
- Huang, L., Sexton, D. J., Skogerson, K., Devlin, M., Smith, R., Sanyal, I., Parry, T., Kent, R., Enright, J., Wu, Q.-L., Conley, G., DeOliveira, D., Morganelli, L., Ducar, M., Wescott, C. R., & Ladner, R. C.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-05
- Volume
- 278
- Issue
- 18
- Pages
- 15532-15540
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2135634425
- Cited by
- 215
- References
- 1
- FWCI
- 9.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.